---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-027262"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T14:54:39.711626+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma plans to resubmit NDA for etripamil in 2Q2024 after FDA Type A meeting

## Summary
- FDA indicated that timing of adverse events had minimal impact on overall etripamil safety profile.
- No additional clinical efficacy or safety trials required before NDA resubmission; standard review expected.
- NDA resubmission for paroxysmal supraventricular tachycardia (PSVT) planned for 2Q2024.
- Cash conservation measures extend operating runway into mid-2025, covering expected PDUFA date.
- Upon FDA approval, Milestone would receive a $75M payment under an existing royalty agreement.

## SEC filing metadata
- accession: 0001104659-24-027262
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465924027262/0001104659-24-027262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465924027262/tm247232d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-027262
- JSON: https://secwatch.observer/filing/0001104659-24-027262.json
- Plain text: https://secwatch.observer/filing/0001104659-24-027262.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.